Market cap
$5 Mln
Recently Viewed
Clear All$0.06
$0.04
(171.43%)
As on 29-Dec-2023 15:49EDT
Market cap
$5 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.3
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-180 Mln
ROE
-1.9 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
0.1
Debt to Equity
0.1
Book Value
$0.2
EPS
$-2.6
Face value
--
Shares outstanding
90,483,000
CFO
$-623.14 Mln
EBITDA
$-776.06 Mln
Net Profit
$-886.25 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Rubius Therapeutics (RUBY)
| -67.4 | -- | -- | -76.2 | -80.5 | -67.7 | -- |
|
BSE Sensex*
| -9.2 | 6.9 | -6.5 | -4.2 | 8.0 | 9.1 | 11.6 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|
|
Rubius Therapeutics (RUBY)
| -98.2 | 27.5 | -20.1 | -40.9 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Rubius Therapeutics (RUBY)
|
0.1 | 5.2 | 0.0 | -230.9 | -- | -238.1 | -- | 0.3 |
| 75.3 | 9,876.5 | 1,091.0 | 202.3 | 31.6 | 31.3 | 44.1 | 17.3 | |
| 44.1 | 11,351.6 | 2,320.1 | 782.6 | 39.0 | 35.5 | 16.1 | 5.3 | |
| 87.4 | 11,058.0 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 64.1 | 7,471.0 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.6 | 155.0 | |
| 264.4 | 7,651.8 | 389.1 | 204.8 | 41.5 | 18.9 | 38.1 | 6.3 | |
| 518.1 | 11,956.1 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 19.9 | |
| 418.6 | 11,812.0 | 2,678.3 | 460.4 | 21.1 | 103.2 | 26 | 19.7 | |
| 99.3 | 7,826.7 | 0.0 | -425.4 | -- | -36.7 | -- | 6.3 | |
| 327.8 | 9,001.1 | 0.0 | -303.3 | -- | -45.8 | -- | 10.2 |
Rubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. The company was formerly known as VL26, Inc and as changed its name to Rubius... Therapeutics, Inc. in 2015. Rubius Therapeutics, Inc. was incorporated in 2013 and is based in Foxborough, Massachusetts. Read more
CEO & Pres
Ms. Dannielle Appelhans
CEO & Pres
Ms. Dannielle Appelhans
Headquarters
Cambridge, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Rubius Therapeutics Inc (RUBY) is $0.06 (NASDAQ) as of 29-Dec-2023 15:49 EDT. Rubius Therapeutics Inc (RUBY) has given a return of -80.48% in the last 3 years.
Since, TTM earnings of Rubius Therapeutics Inc (RUBY) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-0.07
|
1.04
|
|
2021
|
-4.61
|
4.87
|
|
2020
|
-3.79
|
4.34
|
|
2019
|
-4.72
|
2.76
|
|
2018
|
-13.84
|
3.14
|
The 52-week high and low of Rubius Therapeutics Inc (RUBY) are Rs -- and Rs -- as of 01-May-2026.
Rubius Therapeutics Inc (RUBY) has a market capitalisation of $ 5 Mln as on 29-Dec-2023. As per SEBI classification, it is a company.
Before investing in Rubius Therapeutics Inc (RUBY), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.